Clinical Trials | April 22, 2026
Moderna launches late-stage trial of mRNA bird flu vaccine
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
Subscribe To Our Newsletter & Stay Updated
